EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β

Joey A Muns, Erik Schooten, Rychon D J van Dasselaar, Yvet E Noordman, Kevin Adamzek, Arthur C Eibergen, Sebas D Pronk, Sagel Cali, Niels J Sijbrandi, Eugen Merkul, Sabrina Oliveira, Paul M P van Bergen En Henegouwen und 5 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024-10 · 51 (12) · 3545-3558

DOI: 10.1007/s00259-024-06785-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 18.06.2024. Verfasst von Joey A Muns und 16 weiteren Autor:innen. Beteiligte Einrichtung: LinXis Biopharmaceuticals, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Liver Cirrhosis, Receptor, Platelet-Derived Growth Factor beta, Zirconium, Radioisotopes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Hepatic fibrosis develops as a response to chronic liver injury, resulting in the formation of fibrous scars. This process is initiated and driven by collagen-producing activated myofibroblasts which reportedly express high levels of platelet derived growth factor receptor-β (PDGFRβ). We therefore regard PDGFRβ as an anchor for diagnosis and therapy. The Fibrobody® SP02SP26-ABD is a biparatopic VHH-construct targeting PDGFRβ. Here, we explore its potential as a theranostic vector for liver fibrosis.

Methods

Specificity, cross-species binding, and cellular uptake of SP02SP26-ABD was assessed using human, mouse and rat PDGFRβ ectodomains and PDGFRβ-expressing cells. Cellular uptake by PDGFRβ-expressing cells was also evaluated by equipping the Fibrobody® with auristatinF and reading out in vitro cytotoxicity. The validity of PDGFRβ as a marker for active fibrosis was confirmed in human liver samples and 3 mouse models of liver fibrosis (DDC, CCl 4 , CDA-HFD) through immunohistochemistry and RT-PCR. After radiolabeling of DFO*-SP02SP26-ABD with 89 Zr, its in vivo targeting ability was assessed in healthy mice and mice with liver fibrosis by PET-CT imaging, ex vivo biodistribution and autoradiography.

Results

SP02SP26-ABD shows similar nanomolar affinity for human, mouse and rat PDGFRβ. Cellular uptake and hence subnanomolar cytotoxic potency of auristatinF-conjugated SP02SP26-ABD was observed in PDGFRβ-expressing cell lines. Immunohistochemistry of mouse and human fibrotic livers confirmed co-localization of PDGFRβ with markers of active fibrosis. In all three liver fibrosis models, PET-CT imaging and biodistribution analysis of [ 89 Zr]Zr-SP02SP26-ABD revealed increased PDGFRβ-specific uptake in fibrotic livers. In the DDC model, liver uptake was 12.15 ± 0.45, 15.07 ± 0.90, 20.23 ± 1.34, and 20.93 ± 4.35%ID/g after 1,2,3 and 4 weeks of fibrogenesis, respectively, compared to 7.56 ± 0.85%ID/g in healthy mice. Autoradiography revealed preferential uptake in the fibrotic (PDGFRβ-expressing) periportal areas.

Conclusion

The anti-PDGFRβ Fibrobody® SP02SP26-ABD shows selective and high-degree targeting of activated myofibroblasts in liver fibrosis, and qualifies as a vector for diagnostic and therapeutic purposes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisReceptor, Platelet-Derived Growth Factor betaZirconiumRadioisotopesAnimalsMiceHumansRatsTissue DistributionMaleIsotope LabelingCell Line

Stichwörter der Autor:innen

89Zr-immuno-PETActivated myofibroblastsFibrobody®Liver fibrosisPDGFRβTracer and drug conjugates

Substanzen

Receptor, Platelet-Derived Growth Factor betaZirconiumRadioisotopesZirconium-89

Autor:innen und Institutionen

  • LinXis Biopharmaceuticals, Amsterdam, the Netherlands.
  • Department of Biology, Division of Cell Biology, Neurology and Biophysics, Science Faculty, Utrecht University, Utrecht, the Netherlands.
  • Department of Pharmaceutical Sciences, Pharmaceutics Devision, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Pathology, Amsterdam UMC, Amsterdam, the Netherlands.
  • Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Guus A M S van Dongen

Zitieren

APA

Muns, J. A., Schooten, E., van Dasselaar, R. D. J., Noordman, Y. E., Adamzek, K., Eibergen, A. C., Pronk, S. D., Cali, S., Sijbrandi, N. J., Merkul, E., Oliveira, S., van Bergen En Henegouwen, P. M. P., Takkenberg, R. B., Verheij, J., van de Graaf, S. F. J., Nijmeijer, B. A., & van Dongen, G. A. M. S. (2024). Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β. European Journal of Nuclear Medicine and Molecular Imaging, 51(12), 3545-3558. https://doi.org/10.1007/s00259-024-06785-9

Vancouver

Muns JA, Schooten E, van Dasselaar RDJ, Noordman YE, Adamzek K, Eibergen AC, et al. Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(12):3545-3558. doi:10.1007/s00259-024-06785-9

BibTeX
@article{Muns2024,
  author = {Muns, Joey A and Schooten, Erik and van Dasselaar, Rychon D J and Noordman, Yvet E and Adamzek, Kevin and Eibergen, Arthur C and Pronk, Sebas D and Cali, Sagel and Sijbrandi, Niels J and Merkul, Eugen and Oliveira, Sabrina and van Bergen En Henegouwen, Paul M P and Takkenberg, R Bart and Verheij, Joanne and van de Graaf, Stan F J and Nijmeijer, Bart A and van Dongen, Guus A M S},
  title = {Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {12},
  pages = {3545--3558},
  doi = {10.1007/s00259-024-06785-9}
}
Kostenlos starten →